Organisation paid for research Program year 2025 Source: CMS Open Payments

Cleaver Dermatology PC

Neither a doctor nor a teaching hospital

Research payments

$203,950

84 payments

Through program year 2025, Cleaver Dermatology PC is reported as receiving $203,950 in research payments, across 84 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $8,283 2
2024 Research $28,323 10
2023 Research $23,049 8
2022 Research $9,497 7
2021 Research $17,911 8
2020 Research $50,335 25
2019 Research $66,552 24

Breakdown

Who paid Research payments · program years 2019–2025
  1. AbbVie, Inc. $203,950 84 payments
Studies the money was for Research payments · program years 2019–2025
  1. M16-045 $99,109 38 payments
  2. A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up) $27,403 7 payments
  3. M15-999 $17,778 11 payments
  4. Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) $16,360 13 payments
  5. A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis $11,580 6 payments
  6. A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) $8,323 1 payment
  7. A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (Step-Up HS) $8,283 2 payments
  8. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Risankizumab Using a New Formulation for the Treatment of Adult Subjects with Moderate to Severe Plaque Psoriasis $6,331 2 payments
  9. A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis $5,000 1 payment
  10. Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) $1,328 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record